<DOC>
	<DOCNO>NCT01387659</DOCNO>
	<brief_summary>This study design evaluate tolerability Myfortic®/Simulect® combination diabetic patient steroid free regimen . Due diverse ethnicity transplant recipient population , study determine different response , include autoimmunity , Hispanic , Caucasian , patient .</brief_summary>
	<brief_title>Evaluate Tolerability Myfortic®/Simulect® Tacrolimus Without Steroids Three Patient Populations</brief_title>
	<detailed_description>Myfortic® enteric-coated formulation sodium salt derivative mycophenolic acid ( MPA ) administer control kidney graft rejection . Myfortic® develop improve MPA-related upper gastrointestinal ( GI ) side effect delay release MPA reach large surface small bowel . Approximately half kidney transplant recipient United States diabetes mellitus . A recent analysis approximately 30,000 kidney transplant recipient include U.S. Renal Data System show 42 % patient pre-transplant diabetes ( 1 ) . Moreover , 15 % 20 % patient develop diabetes transplantation , condition commonly know post-diabetes mellitus ( 1-3 ) . It previously show rate extent MPA absorption minimally affect diabetes ( 4 ) . Limited data available current literature Myfortic® Simulect® base therapy diabetic patient .</detailed_description>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Basiliximab</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<criteria>1 . Adults ( age 18 65 year age ) , male female Hispanic Caucasian . 2 . Primary kidney kidney transplant patient ( cadaveric , live relate , live unrelated ) 3 . Written inform consent obtain . The patient willing participate study UTMB . 4 . Female negative pregnancy test . 5 . PRA &lt; 20 % . 6 . Enblocks two kidney ( tx 'd time ) allow . 7 . Cold Ischemia time ≤ 30 hr 8 . Hep C patient allow enroll study 1 . Multiorgan transplant 2 . Transplant nonheart beat donor ( NHBD ) dual transplant 3 . ABO incompatible positive cross match 4 . Conditions significantly alter absorption , distribution , metabolism ( except diarrhea ) medication . 5 . Women childbearing potential use contraception method ( ) well woman breastfeed 6 . Inability tolerate oral medication 7 . Inability sign write consent form cooperate investigator 8 . Use investigational medication past 30 day . 9 . Patients severe medical condition ( ) view investigator prohibit participation study ( specify require ) 10 . HIV positive patient 11 . History psychosocial instability 12 . Mental incompetence</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>Myfortic</keyword>
	<keyword>Simulect</keyword>
	<keyword>Steroids</keyword>
	<keyword>Diabetes</keyword>
	<keyword>Transplant</keyword>
	<keyword>Gastric empty</keyword>
	<keyword>Gastric motility</keyword>
</DOC>